Series A – Talk Bio

Berkeley startup raises $106.5M for all‑RNA ‘jumping gene’ therapies

4 weeks ago talkbio0Tagged Berkeley, Cells, Funding, gene therapy, jumping gene, M financing, programmable RNA medicines, Radar Therapeutics, RNA gene, Series A

Radar Therapeutics; Berkeley startup; $106.5M financing; Series A; jumping gene; RNA gene insertion; programmable RNA medicines; cell and gene therapy; biotech funding

Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate

4 weeks ago talkbio0Tagged * * Vivek Ramaswamy * *, 6-amino-1-hydroxyhexane-1,1-diphosphonate, Ambros Therapeutics, Analgesics, Non-Narcotic, Chronic pain, Complex Regional Pain Syndromes, CRPS-1, Diphosphonates, Series A

Ambros Therapeutics; $125 million Series A; chronic pain; complex regional pain syndrome type 1; CRPS-1; neridronate; non-opioid analgesic; bisphosphonate; Vivek Ramaswamy; biotech financing

Jennifer Doudna’s Azalea Therapeutics Launches with $82M to Advance In Vivo CAR-T Using Novel CRISPR Delivery Technology

2 months ago talkbio0Tagged Autoimmune Diseases, Azalea Therapeutics, B-cell malignancies, Cancer Therapeutic Procedure, CAR-T, Clustered Regularly Interspaced Short Palindromic Repeats, EDV technology, Funding, Gene Modification, in vivo, Jennifer Doudna, Series A

Jennifer Doudna; Azalea Therapeutics; CRISPR; in vivo CAR-T; gene editing; EDV technology; cancer therapy; autoimmune disease; Series A funding; B-cell malignancies

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

2 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, Diabetes Mellitus, Insulin-Dependent, Funding, Immune Tolerance, Regeneron, Regulatory T-Lymphocytes, sanofi, Series A, thymus-targeted therapy, Tregs, Zag Bio

Zag Bio; Tregs; regulatory T cells; autoimmune diseases; thymus-targeted therapy; Series A funding; immune tolerance; Type 1 diabetes; AbbVie; Regeneron; Sanofi

Apptronik Raises $350 Million Series A to Scale AI Humanoid Robot Production

3 months ago talkbio0Tagged AI humanoid robots, Apollo robot, Apptronik, Funding, Robotics, Series A, venture capital

Apptronik; Series A funding; AI humanoid robots; Apollo robot; venture capital; robotics

NanoPhoria Secures €83.5M Series A for Heart Failure Therapy; AstraZeneca and Algen Ink Up to $555M AI Drug Discovery Pact

3 months ago talkbio0Tagged AI drug discovery, Algen Biotechnologies, AstraZeneca, Clustered Regularly Interspaced Short Palindromic Repeats, Deal Value, gene modulation, Heart failure, Immunology, nano-in-micro delivery, NanoPhoria, NP-MP1, Series A

NanoPhoria; Series A; heart failure; NP-MP1; nano-in-micro delivery; AstraZeneca; Algen Biotechnologies; AI drug discovery; immunology; CRISPR; gene modulation; deal value